Contact
Privacy Policy

Copyright © DEEPNOID Inc. All rights reserved.

Back to list
Industry AI

DEEPNOID Selected as Lead R&D Institution for MOTIE’s KRW 11.6 Billion Medical-Specialized Hyperscale Generative AI Project

July 31, 2025
DEEPNOID Selected as Lead R&D Institution for MOTIE’s KRW 11.6 Billion Medical-Specialized Hyperscale Generative AI Project

- Five-year, KRW 11.6 billion project to develop medical-specialized multimodal hyperscale generative AI technology
- Development of a medical-specialized hyperscale AI foundation model based on multimodal data, advancing step by step from product development to validation and commercialization
- Global compatibility secured through international healthcare data standards: “We will demonstrate the strength of Korean medical AI technology”

DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), announced that it has been selected as the lead R&D institution for a large-scale AI technology development project worth a total of KRW 11.6 billion, run by Korea’s Ministry of Trade, Industry and Energy (MOTIE).
On July 30, 2025, DEEPNOID was selected for a Digital Healthcare project under the 2025 1st Bio-Health R&D Program, run by MOTIE and the Korea Evaluation Institute of Industrial Technology (KEIT), and completed the agreement signing. The project, titled “Development of Medical-Specialized Multimodal Hyperscale Generative AI Technology,” will be carried out under the overall coordination of the Korea Testing Laboratory (KTL). DEEPNOID will serve as the lead R&D institution, with WENU Inc., the Catholic University of Korea Industry-Academic Cooperation Foundation, the Yonsei University Industry-Academic Cooperation Foundation, and the National Cancer Center Korea participating as research institutions.
DEEPNOID has built extensive experience in generative AI technology. In 2025, it developed M4CXR, a generative AI-based draft report generation model for chest X-ray (CXR). As the lead R&D institution, DEEPNOID will directly plan and carry out the entire process of developing the hyperscale AI foundation model.
The five-year project, which began in 2025, is worth approximately KRW 11.6 billion, including approximately KRW 8.55 billion in government R&D funding. Of this, DEEPNOID will receive KRW 4.98 billion in government funding to develop a medical-specialized hyperscale AI foundation model. The model will be optimized for Korea’s clinical environment and built on multimodal data, including medical images, biosignals, and electronic medical records (EMR).
Going beyond model development, DEEPNOID will implement radiology report generation technology and pursue technology development and commercialization for the global market. To this end, the company plans to apply international healthcare data standards, including HL7, FHIR, and SNOMED CT, from the development stage to ensure global compatibility. It has also established a detailed, step-by-step roadmap from product development to multi-institutional validation and commercialization, considering both real-world clinical usability and global market potential.


Through the project, DEEPNOID ultimately aims to:
- Improve the work efficiency of clinicians
- Enhance diagnostic accuracy
- Reduce societal healthcare costs
- Accelerate the digital transformation of Korea’s healthcare infrastructure
- Strengthen the global competitiveness of Korea’s healthcare industry

“Through this project, we will extend our medical AI technology to hyperscale generative models,” said Woo Sik Choi, CEO of DEEPNOID. “With competition in the medical AI market intensifying, the ability to demonstrate value through commercialization is critical. We will successfully carry out this project to prove the technological strength and competitiveness of Korean medical AI.”
As of July 2025, DEEPNOID was conducting clinical trial procedures to obtain approval for M4CXR from Korea’s Ministry of Food and Drug Safety (MFDS). The company also develops and operates a range of medical AI solutions, including DEEP:NEURO, an AI solution for cerebral aneurysm image interpretation and diagnostic assistance. With this project, DEEPNOID expects to advance its technology and expand its market at the same time.

###